首页> 外文期刊>Liver international : >Optimizing medication management for patients with cirrhosis: Evidence‐based strategies and their outcomes
【24h】

Optimizing medication management for patients with cirrhosis: Evidence‐based strategies and their outcomes

机译:优化肝硬化患者的药物管理:基于证据的策略及其结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Cirrhosis is a morbid condition associated with frequent hospitalizations and high mortality. Management of cirrhosis requires complex medication regimens to treat underlying liver disease, complications of cirrhosis and comorbid conditions. This review examines the complexities of medication management in cirrhosis, barriers to optimal medication use, and potential interventions to streamline medication regimens and avoid medication errors. A literature review was performed by searching PUBMED through December 2017 and article reference lists to identify articles relevant to medication management, complications, adherence, and interventions to improve medication use in cirrhosis. The structural barriers in cirrhosis include sheer medication complexity related to the number of medications and potential for cognitive impairment in this population, faulty medication reconciliation and limited adherence. Tested interventions have included patient self‐education, provider driven patient education, intensive case management including medication blister packs and smartphone applications. Initiatives are needed to improve patient, caregiver and provider education on appropriate use of medications in patients with cirrhosis. A multidisciplinary team should be established to coordinate care with close monitoring, address patient and caregiver concerns, and to provide timely access to outpatient evaluation of urgent/complex issues. Future studies evaluating the clinical outcomes and cost effectiveness of interventions are needed.
机译:摘要肝硬化是与频繁住院和高死亡率相关的病态条件。肝硬化的管理需要复杂的药物治疗方法,以治疗潜在的肝病,肝硬化并发症和合并症。本综述研究了肝硬化,最佳药物障碍的药物管理的复杂性,以及用于简化药物方案的潜在干预措施,避免药物错误。通过2017年12月和文章参考清单来搜索文献综述,以鉴定与药物管理,并发症,依从性和干预措施相关的文章,以改善肝硬化的药物治疗。肝硬化的结构屏障包括纯粹的药物复杂性与这种人群中的药物损伤数量和潜力有关,有缺陷的药物和解和有限的依从性。经过测试的干预措施包括患者自我教育,提供者驱动的患者教育,强化案例管理,包括药物泡罩包装和智能手机应用。需要在适当使用肝硬化患者的药物治疗药物方面来改善患者,护理人员和提供者教育所需的举措。应建立多学科团队,以协调密切监控,地址患者和护理人员的关注,并及时提供对紧急/复杂问题的门诊评估。需要进行评估临床结果和干预措施成本效益的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号